La Roche-Posay unveils its latest MELA B3 product line, showcasing L’Oréal’s most significant advancement in pigmentation treatment: MelasylTM. Developed after 18 years of intensive research and the evaluation of more than 100,000 molecules, this breakthrough represents a pioneering full-spectrum active ingredient in the field of pigmentation science.
First presented at the World Congress of Dermatology 2023, MelasylTM was unveiled alongside the results of a first-of-its-kind epidemiological study involving 48,000 participants from 34 countries across all continents. The study revealed a high prevalence of pigmentation disorders worldwide and a significant impact on quality of life and stigmatisation. Among the findings, 50% reported experiencing a form of pigmentation disorder such as Sun Spots, Post-inflammatory Hyperpigmentation (PIH) and Melasma.
The MELA B3 product lineup heralds a new era in hyperpigmentation treatment, addressing a widespread skin concern that affects millions globally and profoundly impacts both appearance and mental well-being. In La Roche-Posay’s study, 22% of respondents felt less loved by family and friends, 19% felt that they have brought shame to their family and relatives and 20% felt pushed away by their partner due to the strong social stigmatisation linked to pigmentation disorders.
MELA B3 offers essential advantages, including anti-inflammatory properties that combat skin inflammation from UV rays and environmental pollutants. It supports skin renewal by encouraging cell turnover, effectively reducing dark spots. Additionally, the product provides antioxidant defense to protect against free radicals, which trigger melanin production in the skin.
L’Oréal and La Roche-Posay have achieved a groundbreaking advancement in treating one of the most intricate skin conditions with MelasylTM, a novel molecule. This innovative, multi-patented compound works uniquely by intercepting excessive melanin production before it emerges on the skin’s surface, effectively trapping melanin precursors. This breakthrough technology promises visible improvements in just one week of use.
Ashlee Ng, General Manager of L’Oréal Malaysia’s Dermatological Beauty Division, emphasised La Roche-Posay’s commitment to enhancing skin health through science-backed skincare and dermatological expertise. “La Roche-Posay has always been deeply rooted in dermatology. Partnering with dermatologists, we aim to stay at the forefront of skincare science and continue pioneering new breakthroughs for our consumers. The introduction of the MELA B3 product range, featuring MelasylTM, marks a significant step in this direction. We believe this new formulation will have a transformative impact on our consumers, providing a solution that not only addresses hyperpigmentation but also improves overall skin health.
With the combination of MelasylTM, Niacinamide, and La Roche-Posay’s signature thermal spring water, the MELA B3 lineup is highly effective. Once consumers achieve theirdesired results, they can have peace of mind knowing that MELA B3 has been tested with anti-relapse efficacy, significantly reducing the recurrence of hyperpigmentation. Additionally, our products are suitable for sensitive skin as each La Roche-Posay product has been tested extensively, ensuring safety and effectiveness. The L’Oréal Dermatological Beauty Division is proud to bring consumers access to such cutting-edge innovations.”
At the Mela B3 launch event, Consultant Dermatologist Dr. Ch’ng Chin Chwen from Subang Jaya Medical Centre discussed the origins, consequences, and preventive strategies of hyperpigmentation. She also dispelled common misconceptions surrounding this skin condition, aiming to educate and inform the audience about its complexities.
Angeline Tay, Assistant Manager at L’Oreal Research & Innovation Singapore, presented the development process of MelasylTM during the event. She detailed how MelasylTM specifically addresses pigmentation concerns while preserving the natural skin tone of each individual. Additionally, she shared further insights gained from L’Oreal’s extensive research on pigmentation.
Leading La Roche-Posay’s fight against hyperpigmentation is the MELA B3 Serum, offering a comprehensive solution suitable for all skin tones. This innovative formula combines MelasylTM with 10% Niacinamide (Vitamin B3) and other potent ingredients to target key factors contributing to hyperpigmentation, such as:
• Anti-Inflammation: Reduces inflammation caused by UV exposure, pollution, and other environmental stressors.
• Skin Renewal & Exfoliation: Promotes cellular turnover to eliminate excess melanin and visibly diminish dark spots.
• Antioxidant Protection: Shields against free radicals that can stimulate melanin production.
• Dermo-Epidermal Junction Strengthening: Helps prevent melanin deposition in the dermis, addressing more challenging forms of hyperpigmentation.
The MELA B3 range is available at all leading pharmacies and e-commerce platforms. Powered by MelasylTM and Niacinamide, La Roche-Posay presents a 3-step routine for those suffering the physical and mental effects of hyperpigmentation:
1. Begin with the new MELA B3 Clarifying Micro-Peeling Gel Cleanser. (RRP: RM 89.90)
2. Follow with the MELA B3 Serum. (RRP: RM 199.90)
3. Complete your routine with the new MELA B3 Cream SPF 30. (RRP: RM 159.90)
To commemorate the breakthrough in treating pigmentation, MELA B3 introduces a new, luxurious texture. This peach-colored gel has a remarkably lightweight feel, providing excellent skin compatibility for quick absorption. It is alcohol-free, guaranteeing a soothing experience without any risk of irritation.
All the information and images provided by La Roche-Posay.
Follow us on Instagram, Facebook or Telegram for more updates and breaking news.
